SCHEMBL2932063

SCHEMBL2932063

O=C(O)N1CCN(CCCN2CCOCC2)C(=O)C1

nearest known ligand 0.46

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
DPP4 P27487 1/20 0.46
HDAC1 Q13547 1/20 0.44
PARP1 P09874 1/20 0.44
PARP2 Q9UGN5 1/20 0.44
ACHE P22303 1/20 0.42
GLA P06280 1/20 0.41
KMT2A Q03164 2/20 0.39
ALOX15 P16050 1/20 0.39
TSHR P16473 1/20 0.39
HSD17B10 Q99714 1/20 0.39
ALDH1A1 P00352 2/20 0.39
KDM4E B2RXH2 2/20 0.39
SMN1; SMN2 Q16637 2/20 0.39
GAA P10253 1/20 0.38
MAPT P10636 1/20 0.38
POLB P06746 2/20 0.38
SIGMAR1 Q99720 1/20 0.38
LMNA P02545 1/20 0.38
KEAP1 Q14145 1/20 0.38
CYP1A2 P05177 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2932224 0.81 SMN1; SMN2 (0.49) DPP4HDAC1PARP1PARP2KMT2A
SCHEMBL3179062 0.80 MCHR1 (0.43) DPP4PARP1ACHEKMT2ASMN1; SMN2
SCHEMBL19439275 0.77 ITGB3 (0.38) DPP4PARP1PARP2SIGMAR1
SCHEMBL16415209 0.73 ITGB3 (0.39) DPP4SIGMAR1
SCHEMBL20523410 0.73 SMN1; SMN2 (0.52) DPP4ACHEALDH1A1SMN1; SMN2MAPT
SCHEMBL1570929 0.72 KMT2A (0.44) HDAC1PARP1PARP2KMT2AALDH1A1
SCHEMBL1029528 0.72 ADRA1B (0.48) KMT2ATSHRALDH1A1SMN1; SMN2KEAP1
SCHEMBL22717414 0.71 MEN1 (0.62) DPP4PARP1PARP2ACHEKMT2A
SCHEMBL2963862 0.71 P2RX7 (0.33) DPP4
SCHEMBL11181779 0.71 DPP4 (0.42) DPP4ACHEGLAKMT2AALOX15

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1534695-B1 TYROSINE KINASE INHIBITORS MERCK SHARP & DOHME (US) 2010-09-29 EP disclosed
US-20090186871-A1 Tyrosine kinase inhibitors MERCK SHARP & DOHME CORP. 2009-07-23 US disclosed
EP-1534695-A4 TYROSINE KINASE INHIBITORS MERCK & CO INC (US) 2008-06-11 EP disclosed
EP-1534695-A2 TYROSINE KINASE INHIBITORS Merck & Co., Inc. (US) 2005-06-01 EP disclosed
WO-2004014851-A2 TYROSINE KINASE INHIBITORS MERCK & CO., INC. (US) 2004-02-19 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090186871-A1 Tyrosine kinase inhibitors ABL1, JAK2, ERBB2 DPP4 884/4885HDAC1 2335/4885PARP1 3824/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.